Multi-Center Phase Ib Study of Intermittent Dosing of the MEK Inhibitor, Selumetinib, in Patients With Advanced Uveal Melanoma Not Previously Treated With a MEK Inhibitor
Phase of Trial: Phase I
Latest Information Update: 29 Dec 2017
At a glance
- Drugs Selumetinib (Primary)
- Indications Uveal melanoma
- Focus Adverse reactions
- 21 Dec 2017 Planned End Date changed from 1 Jan 2018 to 1 Jan 2019.
- 21 Dec 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
- 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology